FRE Stock Overview
A health care company, provides products and services for chronically ill patients. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Fresenius SE & Co. KGaA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €32.75 |
| 52 Week High | €36.20 |
| 52 Week Low | €24.39 |
| Beta | 1.04 |
| 11 Month Change | -1.77% |
| 3 Month Change | 2.54% |
| 1 Year Change | 20.36% |
| 33 Year Change | -8.35% |
| 5 Year Change | -34.34% |
| Change since IPO | 2,800.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| FRE | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -2.1% | 1.0% | -0.5% |
| 1Y | 20.4% | 19.2% | 8.3% |
Return vs Industry: FRE exceeded the German Healthcare industry which returned 19.2% over the past year.
Return vs Market: FRE exceeded the German Market which returned 8.3% over the past year.
Price Volatility
| FRE volatility | |
|---|---|
| FRE Average Weekly Movement | 2.8% |
| Healthcare Industry Average Movement | 3.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: FRE has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: FRE's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1912 | 177,091 | Michael Sen | www.fresenius.com |
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
Fresenius SE & Co. KGaA Fundamentals Summary
| FRE fundamental statistics | |
|---|---|
| Market cap | €18.49b |
| Earnings (TTM) | -€479.00m |
| Revenue (TTM) | €22.81b |
0.8x
P/S Ratio-38.6x
P/E RatioIs FRE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FRE income statement (TTM) | |
|---|---|
| Revenue | €22.81b |
| Cost of Revenue | €17.48b |
| Gross Profit | €5.33b |
| Other Expenses | €5.81b |
| Earnings | -€479.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.85 |
| Gross Margin | 23.37% |
| Net Profit Margin | -2.10% |
| Debt/Equity Ratio | 60.9% |
How did FRE perform over the long term?
See historical performance and comparison